Sector News

Slow death of Eleven Bio continues as 70% of staff axed

June 24, 2016
Life sciences

Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing the end.

In a SEC filing (not published on its site) the Cambridge, MA-based nano cap announced it was cutting 14 positions in the company–or 70% of its total remaining staff.

In the 8-K form, the biotech said: “The company will eliminate 14 positions across the organization, representing approximately 70 percent of the company’s workforce [and it] expects the restructuring to be substantially complete in the third quarter of 2016.” There will be a total of $900,000 in restructuring costs, with around $600,000 of that being made up from severance packages.

Eleven Bio said that it is also “continuing to review the potential impact of the restructuring, and is unable to estimate any additional restructuring costs or charges at this time.”

Its shares have taken a battering in recent months. In May of last year, its late-stage drug EBI-005 (isunakinra)–an IL-1 receptor inhibitor–flunked a Phase III study for dry eye disease. Then in January, a follow-up Phase III trial to study the drug’s impact on allergic conjunctivitis also flopped, putting serious strain on the company’s dwindling cash supplies.

Then, in March, it was threatened to be booted off the Nasdaq after falling into penny stock territory and failing to comply with its strict equity rules on trading. It was given 180 days to get its act together.

The Third Rock alumni also announced earlier this month that it was to out-license its second, preclinical IL-6 ocular disease drug EBI-031 in its limited pipeline to Roche ($RHHBY) for some much needed financing.

It got $7.5 million upfront, a promise of another $22.5 million for an FDA acceptance of an IND and up to $240 million in future milestones for global rights to the drug and all related IP around it. But as it had burned through much of its cash by the fourth quarter, the upfront payment clearly came too late for the 14 staffers who will be finding a pink slip in their post.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).